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STUDY ON VEP CHANGES IN PATIENTS WITH 
TYPE 2 DIABETES WITHOUT RETINOPATHY 
DIABETES  MELLITUS 
INTRODUCTION 
Diabetes mellitus (DM) is a common metabolic disorder which is 
characterised by the presence of hyperglycemia. Depending on the etiology of 
the diabetes mellitus, factors contributing to hyperglycemia include reduced 
insulin secretion, decreased glucose utilization, and increased glucose 
production.[3] With an increasing incidence worldwide, diabetes mellitus is 
the leading cause of morbidity and mortality in  near  future. 
Diabetes mellitus is one of the oldest diseases recorded as early as 
1500 BC in the abers papyrus of Egypt. 
Our body depends on the metabolism of carbohydrates, amino acids 
and lipids for the integrity of its structure and function. Substrates for this 
metabolism is taken from the plasma. Concentration of this substrates 
depends on the extent of metabolism by insulin sensitive tissues ( hepatocytes, 
Adipocytes, myocytes etc).Therefore insufficiency of insulin and its action in 
diabetes mellitus indirectly affects cells in the body. 
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CLASSIFICATION 
Diabetes Mellitus is mainly divided into two types.  
1.Type 1 Diabetes mellitus- IDDM 
2.Type 2 Diabetes mellitus- NIDDM 
Type 1 Diabetes results from defective insulin secretion. It is also 
called as INSULIN DEPENDENT DIABETES MELLITUS. 
Type 2 DM has variable degrees of insulin resistance, impaired insulin 
secretion and increased glucose production. Also termed as NON INSULIN 
DEPENDENT DIABETES MELLITUS. 
Type 2 Diabetes Mellitus is preceded by a period of abnormal glucose 
homeostasis classified as impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT). 
Other types of  DM  are 
MATURITY ONSET DIABETES OF YOUNG (MODY)  which 
has an autosomal dominant inheritance, characterised by early onset of 
hyperglycemia (usually lesser than 25 years), and impairment in insulin 
secretion. 
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GESTATIONAL DIABETES MELLITUS (GDM) 
Glucose intolerance may develop during pregnancy. Insulin resistance 
is related to the metabolic changes of late pregnancy and the increased insulin 
requirements may lead to IGT. It disappears after delivery but, more chance 
of diabetes later. 
DIAGNOSTIC CRITERIA 
The National Diabetes Data Group and World Health Organization 
have  issued diagnostic criteria for DMTABLE 338-2 
CRITERIA FOR THE DIAGNOSIS OF DIABETES MELLITUS[2] 
• Symptoms of diabetes plus random blood glucose concentration ≥ 
11.1 mmol/L (200 mg/dL)a or 
• Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL)b or 
• Two-hour plasma glucose ≥ 11.1 mmol/L (200 mg/dL) during an oral 
glucose tolerance test 
a-Random is defined as without regard to time since the last meal. 
b-Fasting is defined as no caloric intake for at least 8 h. 
c-The test should be performed using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water; 
Source: Adapted from American Diabetes Association, 2010. 
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RISK FACTORS FOR TYPE 2 DIABETES MELLITUS[3] 
 Race/ethnicity (e.g., African American, Latino, Native American, 
Asian, American, Pacific Islander) 
 Habitual physical inactivity 
 Obesity (BMI  ≥ 25 kg/m2) 
 Family history of diabetes (i.e., parent or sibling with type 2 
diabetes) 
 History of GDM or delivery of baby  > 4 kg. 
 Hypertension (blood pressure  ≥ 140/90 mmHg) 
 HDL cholesterol level  < 35 mg/dL and/or a triglyceride level   
> 250 mg/dL . 
 Previously identified IFG or IGT 
 Polycystic ovary syndrome or acanthosis nigricans 
 History of vascular disease 
Source: Adapted from American Diabetes Association, 2010. 
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EPIDEMIOLOGY 
WHO’s  latest  report says  that India  has 31.7 million diabetic 
subjects at present. This number is expected to increase to 79.4 million by 
2030.[4] 
The incidence of diabetes in Indians varies from that of Europeans by 
Having a younger age of onset. 
          Obesity. 
         Stronger genetic association. 
These differences and the increased prevalence of the disease in India 
indicate the need for more diabetes based studies. 
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CHRONIC COMPLICATIONS OF DM 
With increase in the lifespan of diabetes, long term complications of 
diabetes are increasingly becoming a global health problem. 
Long term complications usually manifest after 10 to 20 yrs.[3] 
Chronic complications can be divided into vascular and   non vascular 
complications. 
The vascular complications of DM further subdivided into 
microvascular (retinopathy, neuropathy, nephropathy) and macrovascular 
complications [coronary artery disease (CAD), peripheral arterial disease 
(PAD), cerebrovascular disease]. 
Non vascular complications include problems such as gastroparesis, 
infections, and skin changes. 
Microvascular 
 Eye disease 
o Retinopathy (non proliferative/proliferative) 
o Macular oedema 
 Neuropathy 
o Sensory and motor (mono- and polyneuropathy) 
o Autonomic 
 Nephropathy 
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Macrovascular 
 Coronary artery disease 
 Peripheral arterial disease 
 Cerebrovascular disease 
Others 
 Gastrointestinal (gastroparesis, diarrhoea) 
 Genitourinary (uropathy/sexual dysfunction) 
 Dermatologic 
 Infections 
 Cataracts &Glaucoma 
 Periodontal disease 
Main symptoms of diabetes mellitus are    Polyuria 
                                                                   Polyphagia 
                                                                   Polydipsia.  
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OCULAR MANIFESTATIONS OF DM                                        
 Lids – Xanthelasma, recurrent stye or hordeolum internum, 
chalazion. 
 Conjuntiva- Telangiectasia, subconjunctival hemorrhage. 
 Cornea-Decreased corneal sensations, higher incidence of infective 
corneal ulcers, delayed epithelial healing, punctuate keratopathy. 
 Iris- Rubeosis iridis. 
 Lens-  snow flake cataract, early onset of posterior subcapsular  
cataract. 
 Vitreous- Posterior Vitreous detachment, Vitreous Hemorrhage, 
Proliferative Vitreo Retinopathy due to fibrovascular  proliferation, 
asteroid bodies. 
 Retina-Diabetic retinopathy, lipaemia retinalis. 
 IOP- hypotony in diabetic ketoacidois, neovascular glaucoma, 
increased   incidence of POAG. 
 Optic nerve –optic neuritis, Anterior Ischaemic Optic Neuropathy, 
optic atrophy. 
 Extraocular muscles-Ophthalmoplegia due to diabetic neuropathy. 
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REVIEW OF LITERATURE 
Study 1 
Heavarian et al. evaluated the retinal and cortical activity by PR-VEP  
in 40 diabetic patients of  which 20 with NPDR and 20 without NPDR and 
compared it with 40 age and sex matched controls .Results showed 
prolongation of P100 latency and  decrease in N75-P100 amplitude which is 
significant. No correlation was found between glycemic control and duration 
of diabetes .He concluded that increased PVEP latency  may be a direct sign 
of Retinal Ganglion Cell damage which takes place before the appearance of 
first ophthalmologically detectable signs of DR. 
Study 2 
Wolff et al. found significant mfVEP implicit time difference between 
controls and diabetes both  with or without retinopathy. 
Study 3 
 Ponte f et al.(1986) studied VEP in 62 IDDM patients  without 
retinopathy and attempted to correlate with the duration of diabetes, insulin 
requirements and HbA1c with VEPs. He found prolongation of p100 latency 
in diabetes. VEP detected by small checks was more involved. Positive 
correlation was found between VEP and duration of diabetes. 
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Study 4 
Lip yang y explained the alteration of PR-VEP in 30 NIDDM patients 
and compared with 30 cases of healthy subjects. The abnormality of PR-VEP 
is related to blood sugar, course of NIDDM, peripheral nerve lesions and 
diabetic neuropathy. 
Study 5 
Karlica et al. in this study ,VEP testing was done in 45 patients who 
were divided into 3 groups. 15 with recently detected type 1 diabetes mellitus, 
15 with long standing  DM and 15 as a control group. Significant difference  
were found between established and recent onset Type 1 DM. Amplitude 
decreases and latency increases as the duration increases. They concluded that 
it is a direct sign of retinal ganglion cell damage which occurs even before 
retinopathy occurs. 
Study 6 
Bhanu et al. in this study, 20 diabetes  patients  of greater than 2yrs 
duration without any complications were compared with 20 control subjects. 
Pattern reversal VEP were done in all patients. The P100 latency is 
significantly prolonged in diabetes when compared to control subjects. 
Significant correlation was found between duration of diabetes and P100 
latency. They concluded that the prolongation is due to structural damage at 
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the level of myelinated nerve fibres or Retinal Ganglion Cell damage before 
DR. 
Study 7 
      Mariani E et al. found prolongation of P 100 latency in diabetes .He 
studied VEP in 35 diabetic subjects without retinopathy. Positive correlation 
is found between VEP and HbA1c and duration of diabetes. 
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DIABETIC RETINOPATHY 
It could be worthwhile to quote sir STEWART DUKE ELDER’S 
words on diabetic retinopathy, “It is one of the major tragedies of 
ophthalmology in the present generation, always common and rapidly 
becoming still more common, affecting the young as well as the aged, 
predictable  but not preventable and relatively untreatable, chronic and 
progressive in its course and leading to blindness in a distressing percent of 
cases”. 
Diabetic retinopathy is one of a chronic progressive sight threatening 
complication of diabetes. It is one of the leading cause of visual impairment 
and blindness among the working age individuals(30 to 60 yrs) in India and 
worldwide.  
Diabetic retinopathy  is commonly described as progressive disease of 
the retinal vasculature with clinical features of increased vascular 
permeability ,vascular occlusion ,retinal ischemia. It is diagnosed clinically by 
the presence of ophthalmoscopically visible lesions in the retinal vasculature 
and background retina. 
The pathology seems to be not only involvement of retinal micro 
vessels but also retinal neurodegenerative changes. 
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Epidemiology 
It is estimated that number of people with diabetic retinopathy will 
increase from 126 million to 191 million in 2030.Diabetic retinopathy  is 
leading cause of blindness in both developed & developing countries . With  
increase in the incidence of  diabetes in India, DR has become 6th  cause of 
blindness in India. 
RISK FACTORS 
 Duration of DM 
Most important  in patients diagnosed before 30 yrs, 50% develop DR 
after 10 yrs and 90% develop DR  after   30 yrs. 
 Severity of diabetes mellitus – poor metabolic control is associated 
with worsening of retinopathy. 
In early stages(mild and moderate NPDR) good metabolic control can 
prevent or delay the progression of Diabetic retinopathy.(DCCT/OSLO 
STUDY). 
 High systolic BP 
 Pregnancy-Associated with rapid progression of DR. 
 
14 
 
Predicating factors are 
1.Poor  pre pregnancy control of DM 
 2.Stage of DR at baseline. 
 3.Pre eclampsia and fluid retention. 
 Patients on Insulin 
 Nephropathy – Associated with worsening of macular edema 
 Renal transplantation may be associated with improvement of macular 
edema. 
 Hyperlipidemia 
 Anaemia 
 Smoking 
 Alcoholism 
 Obesity 
Ocular  factors 
 High myopes  with  choroidal  degeneration  are protective against DR  
due to reduced retinal metabolism. 
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 Cataract removal exaggerate the progression of NPDR & already               
existing DME and lead onto  development of rubeosis. 
 In glaucoma there is reduced metabolic activity and reduced vascular 
perfusion. This  ultimately protects from development of  diabetic 
retinopathy. 
 Unilateral carotid artery stenosis   protects  the  ipsilateral  eye  from 
development of Diabetic retinopathy. 
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ANATOMY OF RETINA 
Retina is the inner most layer of eyeball .It is a transparent, thin, 
delicate membrane .It is the highly developed tissue of the eyeball. It appears 
purplish red in colour due to visual purple rods. 
Retina is a light sensitive layer. The rods and cones absorb the light 
falling on the retina. It contains photosensitive pigments. They initiate 
photosensitive changes which trigger a series of  visual  sensations .Total 
surface area of retina is 10000mm sq. The retinal thickness at the macular 
area is 400 micrometres and at the fovea is 150 micrometers.  
The retina becomes thin as it approaches the equatorial region. It is  
thinnest at ora serrata about 80 micrometres. There are several layers of 
neurons in the retina which are interconnected through synapses. The 
photoreceptors ,rods and cones are directly  sensitive  to  light.  
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ANATOMIC LAYERS OF THE RETINA. 
The layers of the retina from outwards to inwards are as follows. 
o Retinal pigment epithelium. 
o Layer of rods and cones. 
o External limiting membrane. 
o Outer nuclear layer. 
o Outer plexiform lyer. 
o Inner nuclear layer . 
o Inner plexiform layer. 
o Ganglion cell layer . 
o The nerve fibre leyer. 
o Internal limiting membrane. 
SPECIALISED AREAS OF NEURAL RETINA. 
Optic disc 
It is placed 3-4mm nasal to fovea. The optic cup is the central 
depression of variable size. It is the location where axons of ganglion cells 
exit the optic nerve. The major blood vessels enter the eye through this optic 
cup. There are no rods and cones in this area which contributes to 
physiological blind spot. 
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Macula 
Macula is a shallow concavity lying  4mm away from the optic disc at 
the posterior pole .It forms a horizontal eclipse about 2mm long and 1.5 mm 
wide .In the center of fovea there is a small depression of 0.2mm in diameter 
called foveola. It is the place where cones are concentrated. 
Fovea centralis 
It is centrally depressed portion of about 1.85mm  in diameter and 0.25 
mm thickness. They contain only cone ,each being  connected individually to 
one ganglion cell. It represents central 5 degree  of visual field. 
PATHOGENESIS OF DIABETIC RETINOPATHY 
The clinical diagnosis for Diabetic retinopathy is based on the vascular 
abnormalities visible via ophthalmoscope. Recently there  is a growing body 
of evidence which supports the view that Diabetic retinopathy is both  
vascular and neurodegenerative disease. 
METABOLISM AND BLOOD SUPPLY IN RETINA 
The retina  being metabolically active tissue consist of vascular, neural 
and glial cells.  It requires a great amount of energy to support the process of 
phototransduction, maintenance of ionic gradients and synaptic activity. This 
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energy demands are met through the uptake of oxygen and glucose from 
choroidal and retinal circulation. 
The choroidal circulation supplies the outer retina which contributes to 
90% of retina`s oxygen supply. It is influenced to a lesser extent within the 
inner retinal vasculature by the changing oxygen demands. 
By contrast, the retinal circulation contributes to only 10% of the 
retina`s oxygen demand. The degree to which the inner retina is vascularised 
appears to correlate best with degree of oxidative metabolic demand. 
Microvascular Abnormalities in DR. 
Retinal microaneurysms are one of the first visible signs of Diabetic 
retinopathy [24]. In vitro studies which investigate the effect of diabetes on 
leukocyte function suggest that microaneurysms are the first signs of 
enhanced leukocyte-endothelial cell adhesion and entrapment (retinal 
leukostasis) early in the course of the disease [11]. Leukocytes in patients with 
diabetes have been shown to be inflammatory and in turn more adherent to 
the vascular wall, suggesting a role in vascular occlusion. Because of  this 
capillary non-perfusion, neighbouring capillaries dilate. 
The resulting ischemia from vascular occlusion has been shown to 
increase the production of vascular permeability factors such as vascular 
endothelial growth factor (VEGF)[30].  The up-regulation of VEGF expression 
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increases vascular permeability through the breakdown of the blood-retinal 
barrier [30]. Leukocytes that are inflammatory may also play a direct role in the 
breakdown of the blood retinal barrier through the release of proteolytic 
enzymes [45]. 
The breakdown of the blood retinal barrier involves the loss of 
pericytes [12], the degeneration of endothelial cells [46], and the thickening of 
the capillary basement membrane [13]. It is responsible for the leakage of fluid 
and lipoproteins into the retina that is visible via ophthalmoscopy. It also 
allows the extravasation of activated macrophages and neutrophils into the 
interstitial space surrounding neurons which may exacerbate an inflammatory 
process [47]. As retinal ischemia progresses, VEGF induces the growth of new 
blood vessels. These new vessels are fragile and susceptible to hemorrhage, as 
they have incomplete tight junctions, a reduced number of pericytes and 
fenestrations [21]. 
NEURONAL ABNORMALITES IN DR 
Over 40 years ago, Blood worth in 1962  and Wolter in 1961 observed 
neuronal cell loss in histological cross sections from patients with diabetes 
[11,46].This involvement of retinal neurons in the pathogenesis of DR has since 
gained considerable attention. A number of animal and human studies have  
reported neuronal cell loss in addition to metabolic and morphological  
abnormlities both in the presence and absence of clinical Diabetic retinopathy. 
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Neuronal abnormality may be an early indicator of Diabetic 
retinopathy progression.  
RETINAL GANGLION CELLS are the most studied retinal neurons 
in diabetes. Barber et al,[9](1998,2000) reported a reduction of cells in RGC 
layer in streptocin induced diabetes and Type 1 induced rat models. In vitro 
studies have shown that the long term administration of glutamate causes 
swelling of neurons and the death of RGCs. This suggests that glutamate 
excitotoxicity plays a role in the death of RGC. Glutamate is a end product of 
non enzymatic glycation of blood glucose. 
ELECTROPHYSIOLOGICAL EXAMINATIONS could be used to 
investigate disturbances regarding neuronal degeneration in a more objective 
way. 
Most of the electrophysiological studies have concentrated on patients 
with long duration of diabetes. 
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VISUAL ELECTROPHYSIOLOGY 
Visual electrophysiology involves the objective way of measurement 
of neuro-functional changes in visual pathways. VISUAL EVOKED 
POTENTIAL helps in subclinical detection of lesions in the anterior visual 
pathway. The visual evoked potential and the full-field ElectroRetinoGram 
are two visual electrophysiological tests commonly used. 
INTRODUCTION TO THE VISUAL EVOKED POTENTIAL 
The visual evoked potential (VEP) is a invivo non-invasive tool to 
study the functional integrity of visual pathways  from the retina to the visual 
cortex.VEP are primarily the reflection of activity originating from the central 
3 to 6 degree field of vision which are relayed in the occipital cortex. Low 
voltage electrical response (1-20 V) time-locked to a visual stimulus is 
recorded, and signals are averaged from electroencephalographic activity (60-
100V) [25,29].  
Scalp electrodes that are placed over the primary visual cortex (V1) 
records VEP.  VEP is a foveal dominated response as V1 is dominated by the 
central 10 degree of visual field. [28,29] .The response recorded in VEP is field 
potential or radial extracellular potential change that is generated from 
conductance changes in the membranes of active neurons as well as glial cell 
buffering of extracellular potassium[29]. Excitatory postsynaptic potentials 
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generate a surface negativity while inhibitory postsynaptic potentials generate 
a surface positivity [29].  
Standard electrode placement allows for the comparison and analysis 
of waveforms [26]. The electrical response is a voltage change that varies over 
time and is plotted as a waveform [29]. The amplitude and timing to the 
response (latency) elicited by a stimulus are the two major parameters used to 
evaluate the VEP [29]. There is great inter-individual variation in the 
amplitudes of VEPs compared with latency of responses.  
The VEP amplitude can be modified by attention, cranial shape, 
distribution of sulci of the brain and size of the brain [29].The N 75 represents 
the initial excitation with the visual signal arrival  at the layer of 4 in the 
visual cortex. Experiments shows that the excitation at 100ms correlates well 
with the retinal stimulation which is critical for visual perception.  
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TYPES OF VEP 
              Transient VEP  
              Steady state VEP 
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Transient is the one in which the visual stimuli is greater than the 
duration of VEP.The responses are averaged  immediately and results are 
shown. This type is commonly used clinically. 
 Steady state VEP is the one in which ,at stimuli faster than4/sec, 
sequential VEP run together and form a  train of rhythmic activity called 
steady state VEP.Helps in objective meaurement of visual acuity. 
BASIC INSTRUMENTATION  FOR DATA COLLECTION 
AMPLIFIERS: 
For recording evoked potentials, the instruments should be suitable for 
amplifying electrical signals with amplitude down to 0.1 mv. The first stage 
of amplification uses preamplifier which can be placed close to the patient so 
that Leads of the electrode are kept short and the cable between the pre and 
main amplifiers carries signals from a low impedence. 
FILTERS 
These are used to alter the low and high frequency limit. 
ELECTRODES 
Electrodes are attached to the skin by means of adhesive. Separate 
system is used to record impedence from electrode. 
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STIMULATORS 
Sensory stimulation is essential for all Evoked Potentials. They are 
integral in the instrument. This stimulus is synchronised to the sampling 
epoch and trigger point to facilitate viewing the data on the screen. 
1. PATTERN REVERSAL 
Most commonly used stimulus for VEP recording. Here a pattern of 
black and white checks or bar or stripes are used which are repeatedly 
reversed. Black and white checker board pattern is commonly used. 
FLASH VEP 
Cortical response to flash VEP is more wide spread complex and 
variable .Because of this great variability, utility is minimal .Can be used in 
patients with corneal scarring and vitreous haemorrhage.  
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DISPLAY 
Oscilloscope is used to display the evoked potentials which is done 
after averaging. The data are manipulated by digital technique before 
displayed in a Visual display  unit. Further adjustments are done in the display 
mode. 
VISUAL STIMULATION 
Two types of stimulations are used. FLASH and PATTERN. 
FLASH : 
Stroboscope flash is commonly used. It produces a intense pulse of 
bright light. Can be used as a single flash or repeatedly. 
PATTERNS: 
Reversal checker board pattern is commonly used which is generated 
on a Viusal display unit. It can be switched   electromechanically at a required 
rate 2/secs. Apart from this, stationary pattern and pictures can be projected 
onto the screen. The latency of the Evoked potentials depends on the 
luminance of the pattern. 
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RECORDING PATTERN 
Evoked potentials   can be evoked by either change in the pattern in the 
field of vision or change in the luminance or both. 
ELECTRODE PLACEMENT 
Active electrode is placed at OZ or 5cm above the midline from inion. 
Reference electrode positioned 12 cm above the bridge of nose. Ground 
electrode is placed in the midline of forehead. 
3 components are recorded in the mid occipital region.N75, P100, 
N145.The Latency of P100 potential is universally accepted as the most 
useful measure for interpreting the pattern VEP. 
P100 latency 
            P100 response is a part of VEP wave. It is highly consistent and 
reproducible wave form  generated  in the striate and parastriate areas of 
visual cortex. 
The visual stimulus for a VEP is a uniform flash of light (luminance), 
checks or stripes (patterned). Patterned stimuli are ideal for participants who 
are capable of fixating and concentrating on the visual stimulus.  
Most clinical studies use square wave checks; although the more 
appropriate sinusoidal gratings are used frequently for research studies. 
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Square wave gratings produce more artifacts partially attributed to the multi-
dimensional spatial frequency making up the square wave profile [48]. 
The spatial frequency, contrast (luminance and colour), temporal 
frequency and mode of presentation of a stimulus are important determinants 
of visual pathway stimulation [48]. 
Spatial frequency refers to the number of cycles per degree (cpd) of 
visual angle or subtended to an angle of 1° in the eye [29].  Luminance and 
colour contrast refer to the difference in brightness and chromaticity 
respectively between adjacent checks or stripes. It varies from 0-100% and 
can be defined by the Weber or Michelson contrast formulas [29]. 
The temporal frequency refers to the number of stimulus presentations 
per second [29]. Lastly, the mode of presentation refers to whether the stimulus 
is presented in a pattern-reversal or onset-offset manner. Pattern-reversal 
refers to a repetitive pattern that abruptly reverses in luminance or colour 
contrast. Onset-offset refers to a pattern that appears and then disappears, to 
be replaced by a homogenous field of the same mean luminance and 
chromaticity [29]. 
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NON PATHOLOICAL SOURCE OF VEP VARIATION 
 AGE: The latency increases with age in females after 60 yrs. 
 GENDER: Shorter latency and greater amplitude is seen in 
females. 
 VISUAL ACUITY : refractive error and media opacity can 
cause prolonged and low amplitude VEP. 
 ATTENTION AND ACCOMODATION: Can alter the 
amplitude and not the latency. 
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CLINICAL FEATURES AND CLASSIFICATION OF DIABETIC 
RETINOPATHY. 
Diabetic retinopathy is commonly described as a progressive disease of 
the retinal vasculature[5]. It is diagnosed clinically by the presence of 
ophthalmoscopically visible lesions to the vascular structures of the retina and 
related deposits [14]. 
The clinical features of DR are the result of increased vascular 
permeability, vascular closure, and retinal ischemia[5]. 
The classification scale established by the Early Treatment Diabetic 
Retinopathy Study (ETDRS) is the gold standard for Diabetic Retinopathy 
classification. Also called as MODIFIED AIRLIE HOUSE 
CLASSIFICATION. The ETDRS broadly categorizes Diabetic Retinopathy  
as either non-proliferative DR and proliferative  DR. 
Nonproliferative DR (NPDR) refers to the presence of clinically 
detectable microvascular abnormalities before the proliferation of new retinal 
blood vessels (neovascularization). 
NPDR can be subdivided into four stages of severity : 
                    Mild,  
                    Moderate,  
                    Severe, and  
                   Very severe NPDR. 
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Proliferative DR (PDR) is the stage at which neovascularization is 
present [15]. As NPDR progresses to more severe stages, the risk of 
progression to PDR and diabetic macular edema  increases[15]. 
Non proliferative DR   
Mild  NPDR  
Mild  NPDR is characterized by the presence of any or all of retinal 
capillary microaneurysms, retinal haemorrhages, exudates ,cotton wool spots 
upto the level of moderate NPDR. 
MICROANEURYSMS  
Retinal capillary microaneurysms are focal abortive new vessel growth 
or saccular outpouchings of the capillary wall that are typically located in the 
posterior pole of the retina where the pericytes are absent. [42]. 
They appear as small, round red dots about 125 µm in diameter with 
sharp margins and a central light reflex. They tend to appear and disappear 
with time [14].  
Any red spot equal to or greater than 125 µm in diameter with irregular 
margins, particularly if it surrounds a smaller central punctuate lesion, is a 
hemorrhage [15]. 
                                
 
 
NPDR 
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Usually seen in the posterior pole especially temporal to fovea in the 
inner nuclear layer. It is the earliest sign of diabetic retinopathy. 
HARD EXUDATES 
Hard exudates are serum lipoprotein deposits in the extracellular space 
of the retina from leaking retinal capillaries [43]. 
They appear as white or yellowish-white deposits with sharp margins 
in the outer layers of the retina.  
Hard exudates may be dots, confluent patches, or complete rings of 
waxy appearance surrounding prominent microaneurysms or zones of retinal 
edema [14].Seen mainly in the outer plexiform layer. 
Resolves spontaneously over a period of months to years. 
FFA shows hypoflouresence due to blockage of background choroidal 
and retinal capillary fluorescence. 
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Moderate  NPDR 
Moderate  NPDR is characterized by the presence of 
Severe retinal hemorrhages in 1-3 quadrants.or 
Mild intraretinal microvascular abnormalities.(IRMA) 
Significant venous beading in no more than one quadrant. 
cotton-wool spots commonly present. [15]. 
COTTON WOOL SPOTS 
Cotton wool spots, also called soft exudates or nerve fiber infarcts, are 
localized areas of blocked axoplasmic flow in the retinal nerve fiber axons 
such that there is swelling and ultimately the atrophy of fibers.  
         The swelling and atrophy of fibers are the result of occlusion and 
subsequent ischemia in the supplying arterioles of the nerve fiber layer [23]. 
        Cotton wool spots appear as round or oval striated spots with feathered 
borders. They are white, pale yellow-white, or grayish-white [14] and can 
occur transiently following the initiation of strict glycemic control [16]. 
       Resolves within 3 to 6 months.FFA shows no capillary perfusion. 
 
 
  
 
 
MODERATE  NPDR 
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VENOUS ABNORMALITIES 
Venous dilatation. 
Venous beading. 
Venous looping. 
IRMA. 
Venous beading is the thickening and hyaline degeneration of the 
venular wall adjacent to areas of capillary non-perfusion. 
It appears as the focal narrowing or dilatation of the retinal venules and 
is often associated with cotton-wool spots. 
Other venous abnormalities include the abrupt, curving deviation of a 
vein from its normal path (loops), the dilatation of a pre-existing channel or 
proliferation of a new channel (reduplication), white lines along one or both 
sides of the venous column (sheathing), and localized narrowing of venous 
calibre (focal narrowing) [14]. It is a sign of severe NPDR. 
IRMA 
Intra Retinal Microvascular Abnormalities are tortuous, intraretinal 
blood vessels between arterioles and venules adjacent to areas of capillary 
non-perfusion [16].  
They are only visible by fluorescein angiography and can be 
distinguished from normal retinal vessels by their large branching angles and 
irregular calibre. They do not break through the ILM It.sign of severe NPDR.  
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Severe and very severe NPDR 
Severe is characterised by the presence of the following 
The 4-2-1 rule; one or more of: 
1.Severe hemorrhage and microaneurysm in all 4 quadrants. 
2.Venous beading in 2 or more quadrant. 
3.IRMA in atleast one quadrant. 
Very severe NPDR: 
Presence of either two or more of the criteria for severe NPDR. 
HEMORRHAGES                                     
Dot  
Blot/Cluster 
Flame shaped 
Diffuse retinal 
Petaloid 
Preretinal 
Vitreous  
                     Subretinal hemorrhage. 
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DOT HEMORRHAGE 
Lesser than 200 µm. 
Located in the inner nuclear layer, 
Has to be distinguished from microaneurysms. 
BLOT /CLUSTER HEMORRHAGE 
Lesser than ¼ th of the disc diameter. 
Located in the inner nuclear nuclear layer, usually temporal to   
macula. 
Caused due to capillary fragility during the capillary closure 
Resolve in few months 
FFA located within areas of capillary non perfusion. 
FLAME SHAPED HEMORRHAGE 
Lesser than ½ disc diameter. 
Arises from the capillary arteriole ,located in the nerve fibre 
layer. 
Caused by direct pressure on the superficial capillaries by    
increased  Blood pressure. 
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Usually absorbs in three months. 
FFA shows blocked background fluorescence. 
DIFFUSE RETINAL HEMORRHAGE 
                One to two disc diameter 
           Involves the full retina between the arteriole and venule. 
           Resolves in six months 
           FFA non perfusion upto the edge of the vessel. 
Proliferative Diabetic Retinopathy 
In addition to the clinical features of NPDR, PDR is characterized by 
the presence new, fragile blood vessels that arise from the optic disc or 
elsewhere in the retina. They proliferate along the inner retinal surface 
(subhyaloid space) and into the vitreous with or without accompanying 
fibrous strands or sheets. Vascular proliferation into the vitreous can lead to 
subhyaloid or vitreous hemorrhage as well as tractional retinal detachment [14]. 
1.Mild –Moderate PDR 
New vessels on the disc or elsewhere. 
2.High Risk PDR. 
 NVD >1/3-1/2 disc area. 
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 NVD & Vitreous or pre retinal hemorrhages. 
 NVE>1/2 disc area and vitreous or pre retinal hemorrhages 
3.  Advanced  PDR 
 Hemorrhages intraretinal or preretinal. 
 Tractional RD. 
 Tractional retinoschisis,  
 Rubeosis iridis.  
 
 
 
 
 
 
 
 
  
 
 
               PROLIFERATIVE DR 
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DIABETIC MACULAR EDEMA 
Diabetic macular edema (DME) is the accumulation of intraretinal 
fluid due to the breakdown of the blood retinal barrier that involves or 
threatens the center of the macula. It appears as retinal thickening, usually 
along the side of hard exudates and microaneurysms [14]. Clinically Significant 
Macular Edema (CSME) can occur as early as NPDR[14]. 
The ETDRS defines CSME as: 
1. Retinal thickening within 500 µm of the centre of the macula. 
2. Exudates within 500 µm from the centre of macula along with 
retinal thickening 
3. Retinal thickening of one disc area or larger in size ,any part of it 
located within one disc diameter from the centre of macula. 
The foveal avascular zone is the central part of the fovea that is devoid 
of capillaries. Non-perfused inner retinal capillaries surrounding the fovea can 
cause the margins of the foveal avascular zone to become irregular and the 
intercapillary spaces to become wider [42]. Foveal avascular zone 
abnormalities are only visible by fluorescein angiography[14]. 
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DIABETIC MACULOPATHY-    Two types: Type 1 and  Type 2. 
FOCAL: Well circumscribed retinal thickening circinate ring of 
exudates.FFA shows focal hyperflouresence due to leakage and good macular 
perfusion.Treatment is focal laser to all leaking microaneurysms between 500 to 
3000 µm from the center of macula.  DIFFUSE: Edema in the henle’s layer 
associated with diffuse cystoids changes.  
ISCHEMIC: Macula looks normal despite  decreased visual acuity.FFA 
shows enlarged foveal avascular zone. 
MIXED: Both edema, exudates and ischemia. 
Proliferative Vitreo Retinopathy  -  PVR        
 It is the growth and proliferation of preretinal and subretinal membranes. 
Contraction of these membranes causes shortening of the retina leading to strech 
holes or shortening of the retina which detaches the retina. when the proliferation 
matures retinal tissues becomes rigid and immobile making repair more difficult. 
PVR GRADING 
GRADE  A, B, C   by silicone oil study .    
GRADE A, B, C, D BY RETINA SOCIETY TERMINOLOGY 
COMMITTEE.                 
GRADE  A- Appearance of vitreous haze and pigment clumps in the 
vitreous,  
42 
 
GRADE B- Wrinkling of the edges of the retinal tear or the inner retinal 
surface.               
GRADE C - Full thickness  retinal fold with vitreous condensation. 
 GRADE D - Massive retinal folds in all four quadrants and giant retinal 
folds of the entire retina. 
INVESTIGATIONS 
 Urine routine 
 FBS 
 HbA1c 
 Renal parameters 
 Lipid profile 
 Fundus flouresence angiography to find areas of neovascularisation,leakage 
and capillary non perfusion. 
To guide in treatment of CSME 
To identify ischemic maculopathy. 
Differentiate IRMA and new vessel 
Evaluation in hazy media. 
 OCT to study in detail about diabetic maculopathy.                                                
Vitreo macular traction. 
 USG –B scan When opaque media precludes retina examination. 
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MANAGEMENT 
Prevention  
         Treat the underlying conditions  
            Control of blood sugars HbA1c< 7 
           Control of lipid profile  
           Control anaemia 
          Control Diabetic nephropathy 
The treatment for diabetic retinopathy depends mainly on the stage in which 
the patient presented. 
Various options for treating diabetic retinopathy are 
1. Medical Management. 
2. Lasers. 
3. Surgery. 
Medical Management 
 Anti VEGF Agents. 
 Protein kinase C inhibitors. 
 Antioxidants. 
 Aspirin. 
 Statins 
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 Cyclooxygenase 2 inhibitors. 
 Aldose reductase inhibitors. 
 Stomatostatins. 
 Enzymatic vitreolysis. 
EARLY NON PROLIFERATIVE DIABETIC RETINOPATHY 
Mild/moderate NPDR 
 No need for any treatment. 
 Progression of retinopathy is slowed by strict glycemic control. 
 Associated risk factors also should be controlled. 
Severe NPDR 
 Pan retinal photocoagulation. 
Pan retinal photocoagulation :  
  1200 to 1500 spots, each 500 µm in size and 0.1 sec duration. They are 
applied outside the temporal arcade and on nasal side one disc diameter from the 
disc upto equator. 
PRP converts the hypoxic retina into anoxic retina ,thus no angiogenic 
factors are produced. 
It also increases the oxygen diffusion from the choroid. 
           Laser seals the abnormal blood vessel which leaks. 
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Various lasers used are - 
 Argon green, 
 Argon blue green, 
 Krypton red. 
 Frequency doubled Nd yag laser 
 Micropulse diode laser. 
LASER TREATMENT FOR CSME 
Focal Laser 
500 to 1000 microns from the  centre of fovea with spot size of 100 µm  for a 
duration of 0.1 sec. 
Grid Laser 
500 microns from centre of macula and 500 µm from the temporal margin of 
optic disc with spot size 100 microns for 0.1 sec. 
ANTI VEGF AGENTS 
Use of Anti VEGF has revolutionised the treatment of diabetic retinopathy. 
 Ranibizumab (Lucentis) 
 Bevacizumab (Avastin) 
 Pegabtinib (Macugen) 
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 VEGF Trap eye. 
All  ANTI VEGF are given intravitreally under strict aseptic precautions.              
INTRAVITREAL STEROIDS 
These are potent anti inflammatory agents. They inhibit the expression of 
Anti VEGF, effectively reduce the vascular permeability, prevents the blood 
aqueous barrier breakdown. Flucinolone acetonide  intravitreal  implant. 
Intravitreal injection of triamcinalone acetate 2 to 4 mg. Peak action starts at 
one week ,with residual activity persisting for 3 to 6 months. 
TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY 
           All cases of PDR should be treated with PRP. 
           Pan Retinal photocoagulation - is done in a circumferential fashion 500 µm 
from the disc and 2DD from fovea. It can be done in two or more sittings.1200 to 
1600 burns can be applied. 
INDICATIONS FOR PARS PLANA VITRECTOMY 
 Severe persistent vitreous haemorrhage greater than 3months. 
 Progressive tractional RD 
 Combined tractional and rhegmatogenous RD 
 Diffuse DME associated with posterior hyaloid traction. 
 Fibrovascular proliferation 
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 Erythroclastic and ghost cell glaucoma. 
 Recurrent vitreous haemorrhage after laser PRP 
 Anterior segment Neovascularisation with media opacity preventing 
photocoagulation. 
VISION LOSS FROM DR 
 Capillary leakage(macular edema) 
 Capillary occlusion(macular ischaemia,Diabetic papillopathy) 
 Sequelae from ischemia induced neovascularisation. 
 Vitreous Haemorrhage 
 Tractional RD 
 Neovascular glaucoma. 
COMPLICATIONS OF DIABETIC RETINOPATHY 
Tractional RD 
Neovascular glaucoma 
Cataract  
Glaucoma 
Corneal epitheliopathy 
Delayed wound healing following  any intraocular surgery. 
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RECOMMENDED EYE EXAMINATION SCHEDULE 
Diabetes type Recommended Time of 
First Examination 
Recommended Follow up  
Type 1 3-5 years after diagnosis Yearly  
Type 2 At the time of diagnosis Yearly 
Prior to pregnancy 
(Type 1 or Type  2 
Prior to conception and 
early in the first trimester 
No retinopathy to mild 
moderate NPDR every 3-
12 months 
Severe NPDR or wore 
every 1-3 months. 
 
  
  
 
 
 
 
 
PART – II 
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AIM OF THE STUDY 
The Aim of our study is to observe the pattern reversal VEP in a group 
of patients with Type 2 Diabetes mellitus without Retinopathy with varying 
duration of diabetes and varying glycemic control of diabetes mellitus. 
1.   To find whether the PR-VEP  latency is altered in diabetes. 
2.  To correlate the VEP latencies with duration of diabetes. 
3.  To correlate the VEP latencies in patients with varying glycemic 
control of diabetes mellitus. 
4.  To observe and analyse the patients with prolonged VEP 
latencies for development of retinopathy changes in the well 
controlled and poorly controlled groups.  
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MATERIALS AND METHODS 
This is a hospital based comparative study where latencies of diabetic 
subjects are compared with age matched normal subjects. 
          This study is done in the outpatient department of ophthalmology of 
Stanley medical college, Hospital, Chennai during the period of August 2014 
to July 2015. 
METHODS 
STUDY DESIGN- CROSS SECTIONAL PROSPECTIVE STUDY 
GROUP 1- DIABETIC patients without retinopathy 
Group 1A- Duration of DM 1-3 years 
Group 1B- Duration of DM 4 -7 years 
Group1 C-Duration of DM 8 -10years 
GROUP 2-  AGE  MATCHED CONTROL  subjects 
INCLUSION CRITERIA 
Patients with Type 2 diabetes of 30 to 60 years with  duration more 
than one year without any stages of retinopathy changes.. 
Age matched Control subjects.  
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EXCLUSION CRITERIA 
 Any grading of Diabetic Retinopathy. 
 Media opacities. 
 Glaucoma. 
 Optic nerve diseases. 
 Retinal and Macular disorders. 
 Neurological disorders. 
 Systemic medications  with CNS side effects 
RECRUITMENT OF PATIENTS 
Patients with type 2 DM from the department of diabetology were 
involved in the study after explaining about the nature of study. 
Age and sex matched control subjects were taken from master health 
check up attending our Hospital.  
All patients underwent refraction to ensure best corrected visual acuity. 
ELECTROPHYSIOLOGICAL TESTS were done in the Department 
of Neurology. 
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PATIENT INFORMATION 
All patients detailed history regarding the duration of diabetes, recent 
blood sugar values, information regarding any other systemic illness and 
medications were taken prior to test. 
ETHICAL COMMITEE APPROVAL 
This study was approved by members of the ethical committee –
STANLEY MEDICAL COLLEGE, CHENNAI. 
Literature of approval attached. 
CONSENT 
All patients were given consent forms which  has the purpose of the 
study, a clear description of the protocol, benefits of the study, the patient 
right to confidentially as well as right to refree or withdraw from the study at 
any time. 
The details of the consent were carefully & thoroughly explained to all 
patients. All patients were given sufficient time to read the form. Any 
questions or consent were fully addressed. 
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METHODOLOGY  
 Visual acuity of the subjects were recorded and the subjects were 
optimally refracted for viewing distance of the screen. 
 A distance of 100 cms was maintained between screen and subject. 
RMS EMG EP MK2 was used for VEP evaluation. We adhered to the 
current ISCEV guidelines that included details on the measurement of 
electrode impedance as well as amplifier filtering and gain. 
 Subjects were advised to report with dry hair without applying oil. 
Pattern reversal stimuli for VEP were presented. 
VEP were recorded through pattern reversal stimuli using small and 
large checks using a checkerboard stimuli Skin electrodes were used which 
includes 3 scalp electrodes. 
1. Frontal  
2.Occipital. 
3.Grounding. 
The aim was to achieve maximum stimulation of retinal fibres with 
75% contrast and a reversal rate of 1.2 Hz. 
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Uniform illumination was maintained and electrical impedance was 
kept less than 20 ohms. An average of 100 sweeps of stimuli were given to 
each eye. The peak 100 latencies and amplitudes were studied. 
All patients in study group were asked to come for followup after 3, 6 
and 9 months subsequently. In each follow up patients were subjected to 
complete ophthalmological   examination  and VEP Test. 
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STATISTICAL ANALYSIS 
 Data Analysis 
The patients were divided into two groups – Group 1 is patients with 
type 2 DM without retinopathy and  Group 2 are control subjects with normal 
VA. Further the diabetic patients without retinopathy Group was subdivided 
into  
 Group 1A- Duration of  DM 1-3 years 
 Group 1B- Duration of  DM 4 -7 years 
 Group1 C-Duration of  DM 8 -10years 
 Descriptive statistics was done for all data and were reported in terms 
of mean values and percentages. Suitable statistical tests of comparison were 
done. Continuous variables were analysed with the unpaired t test and one-
way ANOVA. Categorical variables were analysed with Fisher Exact Test. 
Pearson’s product–moment correlation coefficients were used to analyze the 
correlation coefficients. Statistical significance was taken as P < 0.05. The 
data was analysed using SPSS version 16 and Microsoft Excel 2007. 
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TABULATION SHOWING THE AGE DISTRIBUTION BETWEEN 
THE DIABETES  AND CONTROL GROUP 
Age  
 
                                                         TABLE 1 
Age Distribution Diabetics % Controls % 
≤ 40 years 3 7.5 3 7.5 
41-50 years 15 37.5 19 47.5 
51-60 years 13 32.5 14 35 
61-70 Years 9 22.5 4 10 
Total 40 100 40 100 
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Age Distribution Diabetics Controls 
N 40 40 
Mean 52.60 50.55 
SD 8.08 6.94 
P value Unpaired t Test 0.2270 
 
The mean age distribution between diabetics and control were 52.60  
and 50.55 respectively.  
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COMPARISON OF GENDER DISTRIBUTION BETWEEN THE 
DIABETES AND  CONTROL GROUP 
Gender  
 
                                                           TABLE 2 
Gender Distribution Diabetics % Controls % 
Male 16 40 21 52.5 
Female 24 60 19 47.5 
Total 40 100 40 100 
P value Fishers exact Test 0.2740 
 
 The male female distribution between diabetes and control groups are  
comparable by  fischer exact test.  
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COMPARISON OF HBA1C LEVELS BETWEEN THE DIABETES 
AND CONTROL GROUP. 
Hb A1C 
 
TABLE 4 
Hb A1C Diabetics % Controls % 
≤ 7 % 16 40 40 100 
> 7 % 24 60 0 0 
Total 40 100 40 100 
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Hb A1C Diabetics Controls 
N 40 40 
Mean 7.06 5.65 
SD 1.24 0.58 
P value Unpaired t Test 0.0000 
 
The  mean HbA1c levels between the diabetes and control group is 
7.06± 1.24 and 5.65±0.58 respectively  which is statistically significant.  
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COMPARISON OF N 75 LATENCY BETWEEN DIABETES  
AND CONTROL GROUP 
N75 
 
                                                        TABLE 5 
N75 Latency  
Distribution in ms 
Diabetic Control P value 
Unpaired t 
Test 
Mean 
(m sec) 
SD 
(m sec) 
Mean 
(m sec) 
SD 
(m sec) 
N75 - Right Eye 73.67 6.49 72.86 5.91 0.5624 
N75 - Left Eye 73.14 5.90 73.63 5.82 0.7079 
N75 - Mean 73.40 5.60 73.24 5.66 0.9008 
 
    The N 75 latencies in diabetic patients is prolonged when compared 
to control  group but statistically  insignificant.  (p>0.05).. 
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COMPARISON OF P 100 LATENCIES BETWEEN  
DIABETES AND CONTROL GROUP 
P100 
 
TABLE 6 
P100 Latency  
Distribution in ms 
Diabetic Control P value 
Unpaired t Test Mean 
(m sec) 
SD  
(m sec) 
Mean 
(m sec) 
SD 
(m sec) 
P100 - Right Eye 107.63 6.17 99.98 1.90 0.0000 
P100 - Left Eye 106.30 6.99 100.34 2.30 0.0000 
P100 – Mean 106.96 6.34 100.16 1.57 0.0000 
The mean P 100 latencies between the diabetes and control group 
is 106.96 and 100.16 respectively. Results shows statistically significant 
correlation between the  diabetes  and control group.(P value < 0.05).  
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COMPARISON OF N145 LATENCIES BETWEEN DIABETES AND 
CONTROL GROUP 
N145 
 
TABLE 7 
N145 Latency  
Distribution in msec 
Diabetic Control P value 
Unpaired t Test Mean 
(m sec) 
SD  
(m sec) 
Mean 
(m sec) 
SD 
(m sec) 
N145 - Right Eye 152.25 12.06 150.52 11.73 0.5173 
N145 - Left Eye 150.35 11.43 153.63 11.10 0.1956 
N145 – Mean 151.30 10.38 152.07 10.49 0.7395 
 
The mean N 145 latencies  in the diabetes and control group were  
151.30 and 152.07 msec respectively group.  
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COMPARISON OF P100-N75 AMPLITUDES BETWEEN DIABETES 
AND  CONTROL GROUP. 
P100-N75 
 
                                                         TABLE 8 
P100-N75 Amplitude 
Distribution in microvolt 
Diabetic Control P value 
Unpaired t 
Test 
Mean 
(V) 
SD  
(V) 
Mean 
(V) 
SD 
(V) 
P100-N75 - Right Eye 4.46 1.65 4.84 1.09 0.2293 
P100-N75 - Left Eye 4.71 1.40 4.91 1.20 0.4926 
P100-N75 – Mean 4.59 1.36 4.88 0.99 0.2790 
 
Though the amplitude is decreased in diabetes when compared to 
control group, p values are not statistically significant.(p value >0.05)  
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CORELATION OF VEP CHANGES WITH DURATION OF 
DIABETES 
VEP Changes Vs Duration of Diabetes 
 
This Bar diagram shows comparison of VEP changes with varying  
duration of diabetes.  
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                                                             TABLE 9 
VEP CHANGES VS DURATION OF DIABETES. 
VEP Changes 
Vs Duration 
of Diabetes 
 
Diabetics 
Group 1A 
(n=14) 
1-3 YRS 
Diabetics 
Group 1B 
(n=17) 
4-7YRS 
Diabetics 
Group 1C (n=9) 
8-10YRS 
Controls  
(n=40) 
P value 
One-way 
ANOVA 
N75 
(m sec) 
74.34±5.65 72.65±4.63 73.34±7.45 73.24±5.66 0.8738 
P100 
(m sec) 
102.94±6.83 107.39±5.25 112.42±1.65 100.16±1.57 0.0000 
N145 
(m sec) 
149.31±8.88 151.32±11.47 154.33±10.81 152.07±10.49 0.7146 
P100-N75 
(V) 
5.06±1.44 4.32±1.29 4.34±1.32 4.88±0.99 0.1995 
 
One way ANOVA test shows significant correlation between P 100 
latencies and duration of  diabetes. As the duration increases the P100 latency 
is more prolonged.  
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CORRELATION ANALYSIS 
VEP Changes Vs Duration of Diabetes 
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                                                     TABLE 10 
Correlation Analysis - VEP 
Changes Vs Duration of Diabetes 
Duration of Diabetes 
Correlation Coefficient P value 
N75 - Mean 0.972722 0.3267 
P100 - Mean 0.903882 0.0000 
N145 - Mean 0.946902 0.5108 
P100-N75 - Mean 0.928023 0.3376 
 
There is a positive correlation between VEP changes and duration of 
diabetes.(p value<0.05) 
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CORRELATION OF VEP CHANGES WITH HbA1C LEVELS. 
VEP Changes Vs Hb A1c Levels 
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TABLE 11 
Correlation Analysis - VEP 
Changes Vs Hb A1C Levels 
Hb A1C 
Correlation 
Coefficient 
P value 
N75 - Mean 0.869707 0.4112 
P100 - Mean 0.952864 0.0000 
N145 - Mean 0.911879 0.1977 
P100-N75 - Mean 0.932844 0.0725 
 
Stastically significant correlation was found between HBa1c levels and 
VEP changes. 
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23
4
no DR-85%
with DR-15%
Tabulation  and  Pie chart showing  total number  of patients with VEP 
changes and retinopathy changes in follow up studies. DR-Diabetic 
retinopathy. 
No of patient  in 
Study group 
Follow up cases Retinopathy 
NO 
retinopathy 
40 27 4 23 
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DISCUSSION 
Pattern Reversal VEP can be used as a simple, non invasive, screening 
tool for early detection of changes in the Diabetic retinopathy. 
P 100 LATENCY 
The difference in the P 100 latencies between the diabetics and control 
group were given in the table  5. Mean P 100 latency in the study group was 
106.16 msec and in the control group it was 100.06 msec. The difference 
between the two is statistically significant.(p value<0.000) .Results show that 
the P100 latencies are prolonged in diabetes when compared to study group 
which indicates that  some  amount of damage to retinal ganglion cell occurs 
even before retinopathy has become clinically evident. 
Also none of our patients had no ocular pathology or Neuro pathology 
causing damage to the anterior visual pathway. 
 Mechanism of damage to retinal ganglion cell in diabetes 
     1.Extracellular glutamate accumulation. 
2.Oxidative stress due to increase in free radical and oxidant 
production or      decrease in antioxidant metabolism. 
    3.Activation of polyol pathway. 
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 Results of our study correlates with that of  many of the studies. 
Karlica et al.[39] showed  prolonged  P100 latencies in patients with type 1 
DM without retinopathy. They concluded  it as   a direct sign of RGC death. 
Another study done by Haeverian et al.[52] Found that VEP helps  in  
identifying the signs of retinal ganglion cell damage even before the onset of 
retinopathy clinically. 
Study done by Wolff et al. showed significant mfVEP implicit time 
difference  between controls and  patients with or without retinopathy. 
Algan et al[40].found prolongation of  P 100 in 50 diabetic patients out 
of which 44 had retinopathy and six patients did not have  retinopathy. 
 Mariani et al.[41] found prolongation of P 100 latency in 35 diabetic 
patients without retinopathy 
 Timothy et al,[44]. in his study suggested retinal ganglion cell die due 
to inflammation, excitotoxicity and oxidative stress. In diabetes there is a 
tendency of ischemia in the neural and other retinal structures which could 
cause generation of microangiopathy, resulting in VEP latency prolongation.   
DURATION OF DIABETES 
In our  study latencies and amplitude of VEP were correlated with 
duration of diabetes which showed statistically significant changes(p value 
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<0.000).This could be explained by poor metabolic control, long exposure of 
Retinal ganglion cell to toxic metabolites. 
Positive correlation was found in some of the previously mentioned 
studies like Ponte et al[38].,Mariani et al.[41] 
GLYCEMIC CONTROL 
In our study long term metabolic control was assessed by HbA1c 
levels. 
VEP changes were correlated with glycosylated  Hb levels which also 
showed  significant correlation  with prolongation of latencies in patients with 
HbA1c levels > 7. 
Similar results were shown by Mariani et al.[41] in his study.  He 
documented acute effects of blood glucose on chromatic VEP in patients with 
diabetes mellitus. They showed three interrelated mechanisms by which   
tissue functions are altered in diabetes in patients with persistent 
hyperglycemia. 
1.Action of polyol  pathway. 
 2.Myoinositol depletion. 
 3.Non enzymatic protein glycosylation. 
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 All the three impairs the Na+  k+ ATPase. This inturn changes the 
sodium, calcium, potassium dependent cellular process of the photoreceptors, 
retinal pigment epithelium and neural tissues in the visual system causing 
VEP abnormality in poorly controlled diabetes.    
AGE AND SEX  
          The mean age between the study and control group is 52.60±8.08  and  
50.55±6.94. 
Gender distribution between study and control groups were 
comparable    by  fishers exact test. 
AMPLITUDE 
        The mean P 100-N 75 amplitude between the study and control  was  
4.59±1.36 and  4.88±0.99 respectively .Although amplitude of PR-VEP   in 
diabetics is decreased when compared to control group, it does not show any 
significant correlation.(p value > 0.05). 
VEP CHANGES AND PROGRESSION TO RETINOPATHY 
Routine ophthalmological examination and  VEP were done in study 
group patients in follow up .Of the 40 diabetic patients in the study group, 
only 27 came for subsequent follow ups .Out of 27 patients with prolonged 
PR-VEP changes,   four of them developed features of early  diabetic 
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retinopathy. All those four patients had poor glycemic control and longer 
duration of diabetes(HbA1c>8).  
Three interrelated mechanisms by which   tissue functions are altered 
in diabetes in patients with persistent hyperglycemia. 
 1.Action of polyol  pathway. 
 2.Myoinositol depletion. 
 3.Non enzymatic protein glycosylation. 
 All the three impairs the Na+  k+ ATPase. This inturn changes the 
sodium, calcium, potassium dependent cellular process of the photoreceptors , 
retinal pigment epithelium and neural tissues in the visual system causing 
VEP abnormality in poorly controlled diabetes.   
Hence the changes in PR-VEP like prolongation of  P100 latency 
indicating  retinal ganglion cell damage can be approached as a probable 
indicator of development of retinopathy if good glycemic control is not 
maintained. Poor control of diabetes is a risk factor for development and early 
progression of retinopathy.  
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SUMMARY 
 40 patients(80 eyes) with  diabetes were compared with 40 controls(80 
eyes). 
 The male female ratio between diabetes and control were propotional . 
 The mean age group between the study group and controls were 52.60 
and 50.55 respectively 
 The mean P 100 latencies between study and control group shows 
significant difference(106.16ms and 100.06 ms) respectively. 
 Although the N 75 and N 145 latencies shows prolongation, they were 
not statistically significant. 
 The P100- N 75 amplitudes also though decreased when compared to 
study group did not show any significant correlation. 
 Correlation coefficient between duration of diabetes and VEP changes 
shows positive correlation. 
 Correlation coefficient between HbA1C levels and VEP changes also 
shows significant difference. 
  Patients with prolonged P100  latency with poor glycemic control 
showed  early signs of diabetic retinopathy.  
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CONCLUSION 
 Diabetic retinopathy is a major complication of diabetes. 
 Several physiological and biochemical changes occur in the retina 
long before structural alterations may  become clinically detected. 
 Neurofunctional changes occur in patients with type 2 diabetes 
earlier than clinically detectable microvascular changes occur. So it 
is important to screen  high risk patients with diabetes both 
clinically as well as by electrophysiologically. 
 Hence VEP can be used as  a safe ,non invasive, objective  method 
for preclinical evaluation and screening of high risk  patients for 
development of  retinopathy in diabetics. 
 In future, it can be used as a screening tool for early detection of 
probable candidates who might develop retinopathy early and 
hence needing closer observation and more strict metabolic control. 
 When the cause for this neural abnormality(Retinal Ganglion Cell 
pathology) is revealed, neuroprotective management to prevent or 
delay the development of diabetic retinopathy would  be possible. 
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- A hospital based study. 
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AÔUøPPøÍ £õº£uØS Gß AÝ©v @uøÁ°Àø» GÚ AÔ¢x 
öPõÒQ@Óß. CÆÁõ#ÂÀ C¸¢x Â»QU öPõshõ¾® Cx 
ö£õ¸¢x® GÚ AÔQ@Óß. 
 C¢u B#Âß ‰»® QøhUS® uPÁÀPøÍ²®, £›@ŒõuøP 
•iÄPøÍ²® ©ØÖ® ]QaøŒ öuõhº£õÚ uPÁÀPøÍ²® 
©¸zxÁº @©ØöPõÒÐ® B#ÂÀ £¯ß£kzvU öPõÒÍÄ® Aøu 
¤µ”›UPÄ® Gß •Ê ©Úxhß Œ®©vUQ@Óß. 
 Põm] öÁÎöPõsk Á¸® vÓß £›@ŒõuøÚ GÆÁøP°À 
Cµshõ® ÁøP }vÈÄ @|õ¯õÎPÎß Bµ®£ {ø» ÂÈzvøµ 
|µ®¦ •ia” £õv¨ø£ PshÔ¯ EuÄ® Gß£øu £ØÔ¯ B#ÂÀ 
£[S öPõÒÍ J¨¦U öPõÒQ@Óß. GÚUS öPõkUP¨£mh 
AÔÄøµPÎß £i |h¢x öPõÒÁxhß C¢u B#øÁ 
@©ØöPõÒÐ® ©¸zxÁ AoUS Esø©²hß C¸¨@£ß GßÖ® 
EÖv AÎUQ@Óß. Gß EhÀ £õvUP¨£mhõ@»õ AÀ»x 
Gvº¨£õµõu ÁÇUPzvØS ©õÓõÚ @|õ#USÔ öuß£mhõ@»õ 
Eh@Ú Aøu ©¸zxÁ AoUS öu›Â¨@£ß GÚ EÖv 
AÎUQ@Óß. 
£[@PØ£Á›ß øPö¯õ¨£® 
 
B#ÁõÍ›ß 
øPö¯õ¨£®ss 
S.NO NAME AGE/SEX
DURATION 
OF DIABETES
 ASSOCIATED 
RISK FACTERS
Hb 
A1C
OCULAR 
EXAM
N75 
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro 
Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro 
Volt)
1 Muthu laxmi 55/F 3 nil 7.5 N 73.1 105.1 151.9 4.71 60 102.5 146.9 5.74
2 Kolammal 62/F 10 CAD 8.5 N 60.1 115.6 163.1 3.2 60 111.9 149.4 7.53
3 Malliga 45/F 2 nil 7 N 77.5 108 153.8 5.02 77.5 108.1 148.1 5.49
4 Pachaiammal 56/F 6 HTN 7.9 N 75 101 173.8 5.08 75 100.7 177.3 5
5 Vijaya 64/F 5 CAD 7.6 N 76.9 105 173.8 5.46 73.8 105.6 170.6 5.32
6 Rajathi 45/F 2 NIL 5 N 64.4 84.4 137.5 3.44 60.5 80 135.6 5.58
7 mariya 54/F 10 HYPERLIPIDEMIA 8.4 N 76.9 114.4 143.8 7.56 75 109.4 140.6 6.47
8 preetha 43/F 3 nil 7.5 N 83.1 108.8 164.4 7.04 82.5 105.6 159.4 7
9 dinesh 54/M 4 nil 6 N 60 97.5 131.3 2.72 60.6 93.1 136.9 1.65
10 murali 65/M 9 nil 8 N 78.8 115.6 163.1 3.27 75 110.6 160.6 3.44
11 vignesh 46/M 1 nil 5.5 N 78.9 105 151.9 5.28 76.9 105.6 146.8 5.86
12 sugumar 61/M 7 HYPERLIPIDEMIA 8.2 N 60 110.3 168.1 2.08 66.9 108 155 2.84
13 venkatesh 36/M 3 nil 6 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
14 thilagavathy 45/F 5 nil 7.8 N 60 111.8 156.6 3.53 81.9 115.6 152.5 4.38
15 ayisha 61/f 8 HTN 8.3 N 70.4 115.6 168.1 3.09 70 103.1 136.9 3.92
16 sasi 45/F 5 nil 7.6 N 80 106.3 137.5 4.03 73.1 106.3 137.5 4.16
17 ishwarya 49/F 7 HTN 8.1 N 72.5 115.6 135.1 3.6 72.5 110 138.1 4.65
18 ramu 47/M 3 NIl 5.5 N 75.1 100.3 150.9 5.5 75.5 99.1 151.8 9.08
19 shanthi 50/F 4 nil 7.4 N 71.9 105.6 141.9 5.73 75.6 106.9 146.9 4.54
20 maadhavi 40/F 2 nil 5 N 80 108.1 142.5 9.4 78.1 107.5 167.5 6.24
21 avarongee 53/F 5 nil 7.8 N 75 102.5 160 3.42 69.4 95 147.5 4.64
22 rubavathy 42/F 3 nil 6 N 68.8 107.5 173.8 3.17 76.3 109.4 161.3 4.12
STUDY GROUP RIGHT EYE LEFT EYE
MASTER CHART
S.NO NAME AGE/SEX
DURATION 
OF DIABETES
 ASSOCIATED 
RISK FACTERS
Hb 
A1C
OCULAR 
EXAM
N75 
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro 
Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro 
Volt)
STUDY GROUP RIGHT EYE LEFT EYE
23 radha 45/F 2 HTN 8 N 70.6 101.9 150.6 4.75 70.6 104.4 145.6 5.24
24 pondurangan 54/M 7 nil 7.4 N 73.8 112.7 141.5 4.36 73.4 115.6 143.6 5.06
25 srinivasan 56/M 3 nil 4.5 N 80.1 106.8 150.3 3.76 82.3 107.7 156.4 3.6
26 ayyakannu 63/M 8 HYPERLIPIDEMIA 8.5 N 83.2 111.5 173.3 4.68 83.4 111.8 176.5 4.07
27 sampath 48/M 6 nil 7.5 N 72.6 106.5 143.6 4.01 72.3 109.4 158.3 5.01
28 padmavathy 50/F 4 nil 7 N 75.3 109.7 146.7 4.08 76.2 110.6 144.8 4.1
29 renganathan 60/M 8 nil 8.2 N 80.4 115.6 168.1 3.06 76 113.1 138.4 4.92
30 vadivambal 55/F 6 nil 6.4 N 73.1 105.1 151.6 4.71 70.6 109.6 153.3 4.06
31 karpagam 46/F 2 nil 7 N 80.6 106.3 135.7 4.01 76.3 106.4 137.5 4.16
32 lenin 60/M 10 nil 8.6 N 60.6 115.3 168.1 2.08 66.9 110 155 2.84
33 rani 55/F 4 nil 6 N 80 108.6 142.5 9.46 78.1 107.6 167.5 6.24
34 subbaiah 67/M 8 HTN 8.1 N 73.8 112.7 141.5 4.75 73.4 115.6 143.6 5.06
35 renu 38/M 1 nil 4.5 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
36 rahmanbai 59/M 4 nil 5.5 N 76.5 106.1 153.7 2.77 71.7 107.2 164.2 3.09
37 raniamma 63/F 6 nil 7.8 N 70.3 114.3 150.1 3.28 72.5 113.4 151.3 3.72
38 ravanamma 61/F 9 nil 8.2 N 78.3 110.4 146.5 4.11 78 111.3 141.3 4.09
39 rathnam 57/F 4 nil 5 N 76.3 109.5 145.4 5.07 77.4 108.6 146.5 5.06
40 raghavan 49/M 3 nil 7.4 N 71.5 103.2 146.5 3.02 72.6 104.4 151.6 3.07
S.NO NAME
AGE/
SEX
DURATION 
OF DIABETES
Hb 
A1C
OCULAR EXAM
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
1 Kolammal 62/F 10 8.5 few dot Hges+,Temporal to macula 64.1 118.6 163.1 4.6 61.4 114.9 149.4 5.6
2 mariya 54/F 10 8.4 microaneurysm+ temporal to macula 70.5 115 143.8 6.4 75 111.4 140.6 6.47
3 ravanamma 61/F 9 8.2 few dot Hges+ST&SN quadrant 78.3 112.3 146.5 5.3 78 111.3 141.3 4.12
4 subbaiah 67/M 8 8.1 few dot Hges+ST quadrant 73.8 112.7 141.5 4.75 73.4 115.6 143.6 5.06
5 Pachaiammal 56/F 6 7.9 N 75 101 173.8 5.08 75 100.7 177.3 5
6 dinesh 54/M 4 6 N 60 97.5 131.3 2.72 60.6 93.1 136.9 1.65
7 murali 65/M 9 8 N 78.8 115.6 163.1 3.27 75 110.6 160.6 3.44
8 venkatesh 36/M 3 6 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
9 thilagavathy 45/F 5 7.8 N 60 111.8 156.6 3.53 81.9 115.6 152.5 4.38
10 ishwarya 49/F 7 8.1 N 72.5 115.6 135.1 3.6 72.5 110 138.1 4.65
11 ramu 47/M 3 5.5 N 75.1 100.3 150.9 5.5 75.5 99.1 151.8 9.08
12 radha 45/F 2 8 N 70.6 101.9 150.6 4.75 70.6 104.4 145.6 5.24
13 pondurangan 54/M 7 7.4 N 73.8 112.7 141.5 4.36 73.4 115.6 143.6 5.06
14 ayyakannu 63/M 8 8.5 N 83.2 111.5 173.3 4.68 83.4 111.8 176.5 4.07
15 sampath 48/M 6 7.5 N 72.6 106.5 143.6 4.01 72.3 109.4 158.3 5.01
16 padmavathy 50/F 4 7 N 75.3 109.7 146.7 4.08 76.2 110.6 144.8 4.1
17 vadivambal 55/F 6 6.4 N 73.1 105.1 151.6 4.71 70.6 109.6 153.3 4.06
18 karpagam 46/F 2 7 N 80.6 106.3 135.7 4.01 76.3 106.4 137.5 4.16
19 rani 55/F 4 6 N 80 108.6 142.5 9.46 78.1 107.6 167.5 6.24
STUDY GROUP FOLLOW UP  AT 9 MONTHS RIGHT EYE LEFT EYE
S.NO NAME
AGE/
SEX
DURATION 
OF DIABETES
Hb 
A1C
OCULAR EXAM
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
STUDY GROUP FOLLOW UP  AT 9 MONTHS RIGHT EYE LEFT EYE
20 renu 38/M 1 4.5 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
21 raniamma 63/F 6 7.8 N 70.3 114.3 150.1 3.28 72.5 113.4 151.3 3.72
22 rathnam 57/F 4 5 N 76.3 109.5 145.4 5.07 77.4 108.6 146.5 5.06
23 raghavan 49/M 3 7.4 N 71.5 103.2 146.5 3.02 72.6 104.4 151.6 3.07
24 Rajathi 45/F 2 5 N 64.4 84.4 137.5 3.44 60.5 80 135.6 5.58
25 preetha 43/F 3 7.5 N 83.1 108.8 164.4 7.04 82.5 105.6 159.4 7
26 vignesh 46/M 1 5.5 N 78.9 105 151.9 5.28 76.9 105.6 146.8 5.86
27 sasi 45/F 5 7.6 N 80 106.3 137.5 4.03 73.1 106.3 137.5 4.16
M = Male
F = Female
HTN = Hyper Tension 
CAD = Coronary Artery Diseases 
S.NO NAME AGE/SEX
DURATION 
OF DIABETES
ASSOCIATED 
RISK FACTORS
Hb A1C
OCULAR 
EXAM
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
1 Kolammal 62/F 10 CAD 8.5 N 60.1 115.6 163.1 3.2 60 111.9 149.4 7.53
2 Pachaiammal 56/F 6 HTN 7.9 N 75 101 173.8 5.08 75 100.7 177.3 5
3 mariya 54/F 10 HYPERLIPIDEMIA 8.4 N 76.9 114.4 143.8 7.56 75 109.4 140.6 6.47
4 dinesh 54/M 4 nil 6 N 60 97.5 131.3 2.72 60.6 93.1 136.9 1.65
5 murali 65/M 9 nil 8 N 78.8 115.6 163.1 3.27 75 110.6 160.6 3.44
6 venkatesh 36/M 3 nil 6 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
7 thilagavathy 45/F 5 nil 7.8 N 60 111.8 156.6 3.53 81.9 115.6 152.5 4.38
8 ishwarya 49/F 7 HTN 8.1 N 72.5 115.6 135.1 3.6 72.5 110 138.1 4.65
9 ramu 47/M 3 NIl 5.5 N 75.1 100.3 150.9 5.5 75.5 99.1 151.8 9.08
10 radha 45/F 2 HTN 8 N 70.6 101.9 150.6 4.75 70.6 104.4 145.6 5.24
11 pondurangan 54/M 7 nil 7.4 N 73.8 112.7 141.5 4.36 73.4 115.6 143.6 5.06
12 ayyakannu 63/M 8 HYPERLIPIDEMIA 8.5 N 83.2 111.5 173.3 4.68 83.4 111.8 176.5 4.07
13 sampath 48/M 6 nil 7.5 N 72.6 106.5 143.6 4.01 72.3 109.4 158.3 5.01
14 padmavathy 50/F 4 nil 7 N 75.3 109.7 146.7 4.08 76.2 110.6 144.8 4.1
15 vadivambal 55/F 6 nil 6.4 N 73.1 105.1 151.6 4.71 70.6 109.6 153.3 4.06
16 karpagam 46/F 2 nil 7 N 80.6 106.3 135.7 4.01 76.3 106.4 137.5 4.16
17 rani 55/F 4 nil 6 N 80 108.6 142.5 9.46 78.1 107.6 167.5 6.24
18 subbaiah 67/M 8 HTN 8.1 N 73.8 112.7 141.5 4.75 73.4 115.6 143.6 5.06
19 renu 38/M 1 nil 4.5 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
20 raniamma 63/F 6 nil 7.8 N 70.3 114.3 150.1 3.28 72.5 113.4 151.3 3.72
21 rathnam 57/F 4 nil 5 N 76.3 109.5 145.4 5.07 77.4 108.6 146.5 5.06
22 raghavan 49/M 3 nil 7.4 N 71.5 103.2 146.5 3.02 72.6 104.4 151.6 3.07
23 Rajathi 45/F 2 NIL 5 N 64.4 84.4 137.5 3.44 60.5 80 135.6 5.58
24 preetha 43/F 3 nil 7.5 N 83.1 108.8 164.4 7.04 82.5 105.6 159.4 7
25 vignesh 46/M 1 nil 5.5 N 78.9 105 151.9 5.28 76.9 105.6 146.8 5.86
26 sasi 45/F 5 nil 7.6 N 80 106.3 137.5 4.03 73.1 106.3 137.5 4.16
27 ravanamma 61/F 9 nil 8.2 N 78.3 110.4 146.5 4.11 78 111.3 141.3 4.09
STUDY GROUP FOLLOW  UP  AT 3 MONTHS RIGHT EYE LEFT EYE
SL.
NO. NAME AGE/SEX
DURATION 
OF IABETES
ASSOCIATED 
RISK FACTORS
Hb A1C
OCULAR 
EXAM
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
1 Kolammal 62/F 10 CAD 8.5 N 60.1 115.6 163.1 3.2 60 111.9 149.4 7.53
2 Pachaiammal 56/F 6 HTN 7.9 N 75 101 173.8 5.08 75 100.7 177.3 5
3 mariya 54/F 10 HYPERLIPIDEMIA 8.4 N 76.9 114.4 143.8 7.56 75 109.4 140.6 6.47
4 dinesh 54/M 4 nil 6 N 60 97.5 131.3 2.72 60.6 93.1 136.9 1.65
5 murali 65/M 9 nil 8 N 78.8 115.6 163.1 3.27 75 110.6 160.6 3.44
6 venkatesh 36/M 3 nil 6 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
7 thilagavathy 45/F 5 nil 7.8 N 60 111.8 156.6 3.53 81.9 115.6 152.5 4.38
8 ishwarya 49/F 7 HTN 8.1 N 72.5 115.6 135.1 3.6 72.5 110 138.1 4.65
9 ramu 47/M 3 NIl 5.5 N 75.1 100.3 150.9 5.5 75.5 99.1 151.8 9.08
10 radha 45/F 2 HTN 8 N 70.6 101.9 150.6 4.75 70.6 104.4 145.6 5.24
11 pondurangan 54/M 7 nil 7.4 N 73.8 112.7 141.5 4.36 73.4 115.6 143.6 5.06
12 ayyakannu 63/M 8 HYPERLIPIDEMIA 8.5 N 83.2 111.5 173.3 4.68 83.4 111.8 176.5 4.07
13 sampath 48/M 6 nil 7.5 N 72.6 106.5 143.6 4.01 72.3 109.4 158.3 5.01
14 padmavathy 50/F 4 nil 7 N 75.3 109.7 146.7 4.08 76.2 110.6 144.8 4.1
15 vadivambal 55/F 6 nil 6.4 N 73.1 105.1 151.6 4.71 70.6 109.6 153.3 4.06
16 karpagam 46/F 2 nil 7 N 80.6 106.3 135.7 4.01 76.3 106.4 137.5 4.16
17 rani 55/F 4 nil 6 N 80 108.6 142.5 9.46 78.1 107.6 167.5 6.24
18 subbaiah 67/M 8 HTN 8.1 N 73.8 112.7 141.5 4.75 73.4 115.6 143.6 5.06
19 renu 38/M 1 nil 4.5 N 75.6 102.5 145.6 5.08 68.8 95.6 135.6 3.66
20 raniamma 63/F 6 nil 7.8 N 70.3 114.3 150.1 3.28 72.5 113.4 151.3 3.72
21 rathnam 57/F 4 nil 5 N 76.3 109.5 145.4 5.07 77.4 108.6 146.5 5.06
22 raghavan 49/M 3 nil 7.4 N 71.5 103.2 146.5 3.02 72.6 104.4 151.6 3.07
23 Rajathi 45/F 2 NIL 5 N 64.4 84.4 137.5 3.44 60.5 80 135.6 5.58
24 preetha 43/F 3 nil 7.5 N 83.1 108.8 164.4 7.04 82.5 105.6 159.4 7
25 vignesh 46/M 1 nil 5.5 N 78.9 105 151.9 5.28 76.9 105.6 146.8 5.86
26 sasi 45/F 5 nil 7.6 N 80 106.3 137.5 4.03 73.1 106.3 137.5 4.16
27 ravanamma 61/F 9 nil 8.2 N 78.3 110.4 146.5 4.11 78 111.3 141.3 4.09
STUDY GROUP FOLLOW UP IN 6 MONTHS Right eye Left eye
S.NO NAME
AGE/
SEX
DURATION 
OF DIABETES
 ASSOCIATED 
RISK FACTERS
Hb A1C
OCULAR 
EXAM
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
N75
(m sec)
P100
(m sec)
N145
(m sec)
P100-N75
(micro Volt)
1 Marimuthu 45/M Nil 6 N 73.1 100.8 135 3.26 72.6 101.5 137.3 3.09
2 Pandiammal 52/F Nil 6.5 N 80 102.3 142.3 4.08 82.1 103.6 143.5 4.56
3 Padmavathy 46/F Nil 5 N 75.6 98.9 145.6 4.75 74 99.1 142.3 4.09
4 Gangadaran 42/F Nil 6 N 60 98.1 168.1 3.06 64.4 98.3 171.4 3.09
5 krishna kumari 50/F Nil 5 N 73.3 97.5 150.6 5.07 74.5 97.6 151.7 5.03
6 Sankareswari 58/F Nil 6.5 N 79.4 101.5 143.4 4.77 78.6 101.7 156.3 4.09
7 Perumal 62/F Nil HTN 6 N 77.5 103.5 173.8 4.08 79 104.5 176.5 5.99
8 Thangapandi 49/M Nil 5.5 N 76.3 99.6 180.1 4.03 76.5 104.7 181.3 4.04
9 Paneerselvam 45/M Nil 6 N 80.3 99.5 153 5.09 89.5 98.7 155.4 5.86
10 Arumugam 58/M Nil 5 N 73.4 105.2 135.1 5.99 74.5 99.9 151.3 5.08
11 Muniyammal 63/F Nil CAD 4.5 N 74.1 100.1 151.7 4.76 70.6 106.5 156.3 4.08
12 Kathirvel 40/M Nil 6 N 72 100.5 140.1 4.08 73.1 100.9 151 4.09
13 Jaanbee 53/F Nil HTN 6.5 N 80.2 103.4 151.6 5.09 81.5 100.6 153.5 5.08
14 Meenakumari 45/F Nil 6 N 75.4 97.3 160.2 6.09 79.4 104.6 162.3 6.88
15 Dhanasekar 44/M Nil 5 N 60.3 99.7 156.2 7.08 66.5 97.1 158.4 7.09
16 Durai 50/M Nil 5.5 N 71.5 100.6 145.3 6.08 73.6 99.3 147.3 7.36
17 Prabhavathy 44/F Nil 6 N 70.5 99.3 153.4 5.98 79.8 100.9 160.5 5.22
18 Anbarasi 56/F Nil HTN 6.5 N 80 97.4 142.5 4.01 78.1 99.6 153.3 4.81
19 Veerammal 52/F Nil 5 N 73.3 104.6 151.3 4.71 70.5 96.6 150.3 3.45
20 Vairam 40/F Nil 5 N 80.9 100 131.5 3.27 75.6 103.8 153.4 4.56
21 RAMAyee 53/F Nil 6 N 73.1 98.5 151.7 4.71 70.6 101.3 168.3 4.07
22 Sugumari 45/F Nil 5.5 N 73.4 98.5 162.3 3.08 74.3 99.7 158.5 7.01
23 Gowri 52/F Nil 5 N 69.5 99.7 156.3 7.33 66.5 100.6 148.7 6.52
24 Mokanddi 55/F Nil 6 N 77.3 101.4 131.5 6.38 75.5 99.1 153.6 5.07
25 manjula 40/F Nil 5.5 N 72.5 101.6 145.4 5.98 73.5 102.6 143.7 5.96
CONTROL GROUP RIGHT EYE LEFT EYE
26 Kulanthaivelu 43/M Nil 5.5 N 69.5 99.5 153.5 5.07 70.3 101 156.4 7.07
27 paranthaman 56/M Nil 5 N 75.6 101.2 161.3 6.08 77.5 99.7 170.3 6.06
28 Majaanbee 46/F Nil 6 N 82.1 98.7 172.5 5.99 80.6 102.2 153.6 4.69
29 Malini 55/m Nil 6.5 N 72.4 100.6 151.1 4.01 73.1 99.3 163.4 4.08
30 prema 65/F Nil CAD 5.5 N 63.6 99.1 145.8 3.52 65.3 100.3 163 5.08
31 Chidambaram 60/M Nil HTN 5 N 70.4 98.7 156.3 4.86 72.5 99.3 160.5 6.223
32 Chinnammal 59/F Nil 5.5 N 74.5 99.4 160.2 6.09 73.3 98.5 163 4.08
33 Kondaiyah 50/m Nil 5 N 73.6 99.8 159.3 4.97 72.3 99 154.3 5.07
34 Padmavathy 45/F Nil 6 N 81.5 100.3 161.5 5.36 82.5 99.7 145.3 4.01
35 Kousalya 50/F Nil 6.5 N 69.3 98.4 150.6 4.5 70.2 100.5 136.7 3.09
36 Banmathi 47/f Nil 5 N 60.5 99.1 138.5 3.78 61.3 98.1 141.3 4.06
37 Pushpam 50/F Nil 6 N 72.1 98.9 140.7 4.36 70.3 99 137.5 4.79
38 Subbaiah 52/F Nil 6.5 N 62.5 96.4 136.3 4.53 63.1 98.4 138.7 3.08
39 Arputham 63/F Nil HTN 5 N 69.3 100.1 139.9 3.69 68.4 96.6 137.2 4.09
40 Chitra 42/F Nil 5.5 N 64.5 99.4 135.1 4 69.6 99.3 138 4.75
